Corporate Europe Observatory

Exposing the power of corporate lobbying in the EU

Les multinationales vampirisent le Sommet de la Terre

  • Dansk
  • Nederlands
  • English
  • Suomi
  • Français
  • Deutsch
  • Ελληνικά
  • Italiano
  • Bokmål
  • Polski
  • Portuguese
  • Română
  • Slovenščina
  • Español
  • Svenska
 

A crusade for big business-friendly deregulation, waged during José Manuel Barroso's Presidency of the European Commission, shows no signs of stopping. This neoliberal push to weaken or block new legislation appears likely to expand with Jean-Claude Juncker's new Commission team.
Our correspondence with Pr. Anne Glover, the current Chief Scientific Adviser to the President of the European Commission (CSA), on her role in the European Commission's review of endocrine disrupting chemicals shows how the very existence of her position was used by business-friendly interests to convey key messages to the top of the European Commission's hierarchy, playing a determining role in the massive delay now inflicted to the European Commission's handling of this important public health regulation. We ask that the CSA position is not renewed in the new Juncker Commission.
Corporate Europe Observatory (CEO) today criticised the plenary vote of MEPs to approve the Jean-Claude Juncker Commission.
CEO just responded to the European Ombudsman’s public consultation on transparency in the negotiations over the Transatlantic Trade and Investment Partnership (TTIP), outlining suggestions for ending the secrecy in the EU-US trade talks.
A crusade for big business-friendly deregulation, waged during José Manuel Barroso's Presidency of the European Commission, shows no signs of stopping. This neoliberal push to weaken or block new legislation appears likely to expand with Jean-Claude Juncker's new Commission team.
Our correspondence with Pr. Anne Glover, the current Chief Scientific Adviser to the President of the European Commission (CSA), on her role in the European Commission's review of endocrine disrupting chemicals shows how the very existence of her position was used by business-friendly interests to convey key messages to the top of the European Commission's hierarchy, playing a determining role in the massive delay now inflicted to the European Commission's handling of this important public health regulation. We ask that the CSA position is not renewed in the new Juncker Commission.
Will EFSA become more transparent, and to lobbyists or scientists? After its public consultation on its draft transparency policy, the Authority must now choose.
Corporate Europe Observatory (CEO) today criticised the plenary vote of MEPs to approve the Jean-Claude Juncker Commission.

Corporate Europe Forum